Donanemab s benefits greater for patients in early disease: Trial alzheimersnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from alzheimersnewstoday.com Daily Mail and Mail on Sunday newspapers.
Questions about whether donanemab - and two similar drugs from US pharma giants - are really the answer to combating the devastating disease remain unanswered.
Alzheimer’s disease patients in the earliest stages of their disease benefited the most from Eli Lilly drug donanemab, which is expected to receive an FDA decision by the end of 2023. Full results from the drug’s pivotal study were presented during the during the Alzheimer’s Association International Conference.
Remarkable Alzheimer s Drug Reduces Cognitive Decline, Study Shows menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.